Trial · NCT00657150
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period | 28-35 days | Full Analysis Set (randomised, had taken at least 1 dose of oral or subcutaneous trial medication, had undergone surgery, had evaluable negative venogram for both distal and proximal DVT in both legs or positive venography in any 1 segment of 1 or both legs, or confirmed symptomatic DVT, PE or death during the treatment period.) | Participants | NUMBER |
| SECONDARY | Number of Participants With Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period | 28-35 days | Full Analysis Set-major (randomised, had taken at least 1 dose of oral or subcutaneous trial medication, had undergone surgery, had evaluable negative venogram for proximal DVT in both legs or a positive venogram for proximal DVT in either leg or confirmed symptomatic proximal DVT, PE or death related to VTE during the treatment period.) | Participants | NUMBER |
| SECONDARY | Number of Participants With Proximal Deep Vein Thrombosis During Treatment Period | 28-35 days | Full Analysis Set - pDVT (all patients who had been randomised, had taken at least 1 dose of oral or subcutaneous trial medication, had undergone surgery (i.e. a date of surgery was reported), evaluable negative venogram for proximal DVT in both legs or positive venogram in either leg or confirmed symptomatic proximal DVT) | Participants | NUMBER |
| SECONDARY | Number of Participants With Total Deep Vein Thrombosis During Treatment Period | 28-35 days | Full Analysis Set-tDVT (randomised, had taken at least 1 dose of oral or subcutaneous trial medication, had undergone surgery, evaluable negative venogram for both distal and proximal DVT in both legs or positive venography in any 1 segment of 1 or both legs, or confirmed symptomatic DVT.) | Participants | NUMBER |
| SECONDARY | Number of Participants With Symptomatic Deep Vein Thrombosis During Treatment Period | 28-35 days | Full Analysis Set - op (all patients who had been randomised, had taken at least 1 dose of oral or subcutaneous trial medication or had undergone surgery (i.e. a date of surgery was reported) | Participants | NUMBER |
| SECONDARY | Number of Participants With Pulmonary Embolism During Treatment Period | 28-35 days | Full Analysis Set - op (all patients who had been randomised, had taken at least 1 dose of oral or subcutaneous trial medication or had undergone surgery (i.e. a date of surgery was reported) | Participants | NUMBER |
| SECONDARY | Number of Participants Who Died During Treatment Period | 28-35 days | Full Analysis Set - op (all patients who had been randomised, had taken at least 1 dose of oral or subcutaneous trial medication or had undergone surgery (i.e. a date of surgery was reported) | Participants | NUMBER |
| SECONDARY | Number of Participants With Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period | 3 months | Patients with any data available during follow-up | Participants | NUMBER |
| SECONDARY | Number of Participants With Bleeding Events (Defined According to Modified McMaster Criteria) During Treatment Period | 28-35 days | All patients who had been randomised, had taken at least 1 dose of oral or subcutaneous trial medication. | Participants | NUMBER |
| SECONDARY | Blood Transfusion | Day 1 | Treated and operated patients | participants | NUMBER |
| SECONDARY | Volume of Blood Loss | Day 1 | Treated and operated patients | mL | MEAN |
| SECONDARY | Laboratory Analyses | First administration to end of study | Treated patients | participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00657150/outcomes